Potential diabetes breakthrough
- Future Students
- Current Students
- Research and Teaching
- Partners and Community
- About JCU
- Celebrating 50 Years
- Anton Breinl Research Centre
- Agriculture Technology and Adoption Centre
- Living on Campus
- Advanced Prawn Breeding Research Hub
- Advanced Analytical Centre
- Applying to JCU
- Australian/NZ Students
- Australian Lions Stinger Research
- Boating and Diving
- Australian Tropical Herbarium
- Careers at JCU
- Association of Australian University Secretaries
- Careers and Employability
- Australian Quantum & Classical Transport Physics Group
- Centre for Tropical Bioinformatics and Molecular Biology
- College of Business, Law and Governance
- College of Healthcare Sciences
College of Medicine and Dentistry
- News & Stories
- Get Involved
- Short Courses & Professional Development
- Clinical Electives (non-JCU students)
- Making Rural Health Matter
- JCU GP Training
- Northern Queensland Regional Training Hubs
- Contact us
- College of Science and Engineering
- COVID-19 Advice
- Cyclone Testing Station
- The Centre for Disaster Studies
- Daintree Rainforest Observatory
- Diploma of Higher Education
- Discover Nature at JCU
- Division of Research and Innovation
- Division of Tropical Environments and Societies
- Division of Tropical Health and Medicine
- Staff Intranet
- Economic Geology Research Centre
- Elite Athletes
- Financial and Business Services Office
- Foundation for Australian Literary Studies
- Gender Equity Action and Research
- Give to JCU
- Information for JCU Cairns Graduates
- Graduate Research School
- JCU Ideas Lab
- Indigenous Education and Research Centre
- Indigenous Legal Needs Project
- IT Services
- Information for Agents
- International Students
- JCU College
- JCU Connect
- JCU Contact Information
- JCU Eduquarium
- JCU Global Experience
- JCU Motorsports
- JCU Prizes
- JCU Sport
- Language and Culture Research Centre
- Marine Geophysics Laboratory
- New students
- Off-Campus Students
- Office of the Provost
- Office of the Vice Chancellor and President
- Virtual Open Day
- Outstanding Alumni Awards
- Parents and Partners
- Pathways to university
- Planning and Performance
- Planning for your future
- Professional Experience Placement
- Queensland Research Centre for Peripheral Vascular Disease
- Rapid Assessment Unit
- Researcher Development Portal
- Safety and Wellbeing
- Scholarships @ JCU
- State of the Tropics
- Strategic Procure to Pay
- Student Equity and Wellbeing
- TQ Maths Hub
- Unicare Centre and Unicampus Kids
- VAVS Home
- Work Health and Safety
- WHOCC for Vector-borne & NTDs
- Australian Institute of Tropical Health & Medicine
Can a common diabetes drug slow aneurysm growth?
A new study by researchers at the Australian Institute of Tropical Health and Medicine (AITHM) at James Cook University has found a common diabetes medication could limit the need for surgery in patients suffering from a potentially life threatening aneurysm.
Abdominal Aortic Aneurysm (AAA) is a progressive ballooning in a weakened section of the body’s main artery, which increases the risk of arterial rupture and fatal bleeding. It kills approximately 1000 Australians per year, often without warning.
Currently patients with AAA are forced to wait for expensive and invasive surgery as their only option to treat the potentially life threatening condition.
However, in a recent study published in the British Journal of Surgery, AITHM researchers found that AAA growth rates were significantly lower in patients taking Metformin, a commonly prescribed anti-diabetes medication.
“No drugs have been shown to be effective in reducing AAA growth, meaning that patients have to undergo surgery once their aneurysm is considered to be at high risk of rupture,” says study co-author, Dr Joe Moxon.
“We measured AAA growth in patients using CT, or ultrasound scans and found that those on Metformin had significantly slower aneurysm growth rates.”
The results are an important step towards testing a new method of treating patients with AAA.
“The discovery of a drug to slow AAA growth has the potential to reduce the number of people requiring surgery, and improve patient quality of life by lowering anxiety levels associated with a life-threatening condition. With reduced access to specialist care, this has an even greater impact for those in rural and remote locations.
“Currently patients are told that they have an aneurysm growing inside them, however we are unable to do anything to help slow the process. Patients enter a ‘watchful waiting’ process to monitor their aneurysm, which can cause stress and anxiety, which impacts their mental and social wellbeing.
“Discovery of a medicine which effectively slows AAA growth could revolutionise patient management,” Dr Moxon says.
Lead researcher Professor Jon Golledge says further research is required to assess the effect of the drug in non-diabetic patients.
“Consistent previous research findings suggest that diabetes protects against AAA growth. There are a number of suggested reasons for this including the fact the people with diabetes have stiffer arteries which are resistant to the weakening process.
However, recently it has been suggested that this protective effect may actually be due to the medications that patients take to control their blood sugar levels.
“Our data suggest that Metformin may be associated with slower AAA growth, although this is difficult to discern since all patients taking Metformin also have diabetes. We want to see whether our observations of slower AAA growth in patients receiving Metformin reflect a true drug effect or are simply the result of diabetes. To do this, it’s necessary to conduct a well-designed randomised control trial in AAA patients who do not have diabetes.
“If successful, identifying a drug that slows AAA growth will have profound implications for patients.
“It would be incredibly beneficial to find an inexpensive and accessible drug to provide a proactive treatment option rather than waiting for surgical intervention,” Professor Golledge says.
The study was published in the British Journal of Surgery and undertaken by researchers at the Queensland Research Centre for Peripheral Vascular Disease based at James Cook University.